Virpax Pharmaceuticals (VRPX)
OTHER OTC:VRPX
Want to see VRPX full AI Analyst Report?
VRPX Stock Chart & Stats
$0.01
-$0.03(-8.69%)
At close: 4:00 PM EST
$0.01
-$0.03(-8.69%)
Day’s Range― - ―
52-Week Range$0.01 - $0.46
Previous CloseN/A
Volume440.71K
Average Volume (3M)2.23K
Market Cap
$13.79K
Enterprise Value-$1.50M
Total Cash (Recent Filing)$1.51M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta13.57
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,242,504
10 Day Avg. Volume1,988
30 Day Avg. Volume2,232
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-44.23
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-108.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.17
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Safety ProfileThe Molecular Envelope Technology (MET) study found no moderate-to-severe adverse events, indicating safety.
Study ResultsProbudur found to successfully reduce pain in rat model, with positive study results consistent with prior studies.
Bears Say
Financial ConstraintsInsufficient capital to materially advance into Phase 2 studies for both Probudur and Envelta.
Leadership InstabilityVirpax's CEO and CFO both resigned, along with multiple board members, due to disagreements with execution of policies, practices, and procedures.
Regulatory ComplianceVirpax received a deficiency letter from Nasdaq since the stock was trading below <$1 for 30 consecutive business days and has until a specific date to regain compliance.
Virpax Pharmaceuticals News
VRPX FAQ
What was Virpax Pharmaceuticals’s price range in the past 12 months?
Virpax Pharmaceuticals lowest stock price was $0.01 and its highest was $0.46 in the past 12 months.
What is Virpax Pharmaceuticals’s market cap?
Virpax Pharmaceuticals’s market cap is $13.79K.
When is Virpax Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Virpax Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Virpax Pharmaceuticals overvalued?
According to Wall Street analysts Virpax Pharmaceuticals’s price is currently Overvalued.
Does Virpax Pharmaceuticals pay dividends?
Virpax Pharmaceuticals does not currently pay dividends.
What is Virpax Pharmaceuticals’s EPS estimate?
Virpax Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Virpax Pharmaceuticals have?
Virpax Pharmaceuticals has 1,242,504 shares outstanding.
What happened to Virpax Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Virpax Pharmaceuticals?
Currently, no hedge funds are holding shares in VRPX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Virpax Pharmaceuticals
Virpax Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical enterprise, dedicated to pioneering diverse drug-delivery systems and novel drug-releasing technologies. Its core focus lies in developing advanced, non-opioid and non-addictive solutions for pain management, alongside therapies targeting central nervous system disorders. The company's current investigational pipeline features several preclinical product candidates. These include Epoladerm, a topical nonsteroidal anti-inflammatory drug (NSAID) designed to address chronic osteoarthritis of the knee, and Probudur, an injectable liposomal gel formulated as a local anesthetic for managing post-operative pain. Also in development are Envelta and PES200, both nanotechnology-based intranasal spray drug candidates engineered to deliver metabolically labile peptide drugs directly to the brain. Further candidates comprise AnQlar, an antiviral barrier solution intended to prevent or lessen the severity of human viral infections such as influenza and SARS-CoV-2, and VRP324, an experimental nasal formulation aimed at enhancing the transport of cannabidiol into the brain. Virpax Pharmaceuticals, Inc. was established in 2016 and is based in Berwyn, Pennsylvania.
Technical Analysis
Scinai Immunotherapeutics
―
Aditxt
―
CERo Therapeutics Holdings
―
Psyence Biomedical
―
CDT Equity
―
Ownership Overview
―
Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---